Tag Archives: cardiac

Device Regulators, MHRA, Publish Draft for Comment on Vigilance Systems for CE-Marked Medical Devices – Cardiac Ablation Catheters

Device Regulators, MHRA, Publish Draft for Comment on Vigilance Systems for CE-Marked Medical Devices – Cardiac Ablation Catheters.

Full Text Here

This guidance document gives advice to manufacturers on the notification of adverse incidents involving cardiac ablation catheters (CACs) under the Medical Devices
Vigilance System. It is intended to facilitate the uniform application and implementation of Medical Devices Directive 93/42/EEC and amended by 2007/47/EC. It is
supplementary to, and should be read in conjunction with, the European Commission Guidelines on a Medical Devices Vigilance System, and MHRA Directives Bulletin 3
- Guidance on the operation of the EU vigilance system in the UK . This guidance sets out the Medicines and Healthcare products Regulatory Agency’s
(MHRA) views on the interpretation of the Medical Devices Regulations. It should not be considered to be an authoritative statement of the law in any particular case as it is
intended as guidance only. Manufacturers and others should consult the legislation referred to, making their own decisions on matters affecting them in conjunction with
their lawyers and other professional advisers. The MHRA does not accept liability for any errors, omissions, misleading or other statements in the guidance whether
negligent or otherwise. An authoritative statement could be given only by the courts.

Development Consultancy

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 Device Regulators, MHRA, Publish Draft for Comment on Vigilance Systems for CE Marked Medical Devices   Cardiac Ablation Catheters

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes Device Regulators, MHRA, Publish Draft for Comment on Vigilance Systems for CE Marked Medical Devices   Cardiac Ablation Catheters

New Draft FDA Guidance on Somatic Cell Therapy for Cardiac Disease

The FDA CBER (Centre for Biologics Evaluation and Research) has released some draft guidance for industry. it is intended to provide sponsors who are developing cellular therapies for the treatment of cardiac disease, with recommendations on the design of preclinical and clinical studies and on the Chemistry Manufacturing and Controls information needed for IND’s (Investigational New Drug Applications), for cellular therapies aimed at cardiac disease. The guidance also provides recommendations regarding the information that you should submit on the product’s delivery system.

The Background to this guidance is expanded upon!

Despite advances in medical and surgical therapies, heart disease remains a major cause of morbidity and mortality. There is an increasing number of patients with significant morbidity despite optimal medical management. Cardiac cellular therapies have emerged as a field designed to advance the treatment of heart disease through the regeneration of cardiac tissues.

There has been much debate about how to interpret differing data and theories on the mechanism of action of cell therapies in cardiovascular disease. This guidance appears to be an attempt to set some standards in the design of these trials.

If you want to read the full guidance click here.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug  evelopment target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida consultants freestrategyconsultation 515x64 New Draft FDA Guidance on Somatic Cell Therapy for Cardiac Disease

Free Strategy Consultation - Biotech Pharma Regualtory